**Target population**
Adults with spasticity and reduced upper limb function due to stroke > 1 month previously

Participants identified from:
Stroke services, rehabilitation services, stroke clubs, day centres

**Screening visit**

**Initial assessment**

**CENTRAL RANDOMISATION**
Newcastle University

**INTERVENTION**
Botulinum toxin type A + 4 week upper limb therapy programme (one hour twice per week provided by study therapist)

**CONTROL**
4 week upper limb therapy programme (one hour twice per week provided by study therapist)

**1 MONTH**
Blinded outcome measures
- Upper limb function – Action Research Arm Test, Nine Hole Peg Test
- Motor impairment – Motricity Index & grip strength
- Assessment of spasticity
- Upper limb pain (numerical rating scale)
- Patient-selected upper limb goal attainment
- Disability – Barthel ADL Index
- Quality of life – Stroke Impact Scale and Euroquol-5D

**3 month**
Blinded assessment: outcome measures as above
Clinical assessment by study therapist. If required:
I : further botulinum toxin type A and upper limb therapy. C: further upper limb therapy

**6 month and 9 month**
Clinical assessment by study therapist. If required:
I : further botulinum toxin type A and upper limb therapy. C: further upper limb therapy

**12 month**
Blinded assessment: outcome measures as above
Clinical assessment by study therapist. If further spasticity treatment required, refer to local services or regional spasticity clinic

**Abbreviations:**  I intervention     C control